Colorado Supreme Court Quotes I. Glenn Cohen: "In re Marriage of Rooks— Divorce—Assisted Reproduction—Embryos"

Justice William W. Hood III, quoting I. Glenn Cohen (Faculty Director)

The Colorado Supreme Court in a dissent by Justice Hood, joined Coats and Samour, quotes I. Glenn Cohen.  From the dissent:  For the non-consenting donor, there are several harms that may be inflicted, each of which derives “from…

Read More

Colorado Supreme Court creates rules for divorced couples divided over fate of their frozen embryos: Case could potentially be considered by U.S. Supreme Court

The Denver Post, October 29, 2018
Elise Schmelzer, quoting I. Glenn Cohen (Faculty Director)

From the article:  While other states have considered similar cases, the guidelines issued by the Colorado court are some of the most specific created by any state on the issue, said Glenn Cohen, a Harvard University law professor who specializes…

Read More

Coming today: Trump’s most aggressive drug pricing move yet

Politico, October 25, 2018
Dan Diamond, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Some policy experts cheered Trump's ideas, although they had questions about how the plan would work — "If companies won't sell to Medicare at the benchmark price, what happens?" mused Rachel Sachs of…

Read More

Consortium Seeks to Evaluate, Enhance HRPP Effectiveness

AAHRPP Advance, October 23, 2018
AAHRPP featuring work by Holly Fernandez Lynch (Former Executive Director) and colleagues

From the article: What are the outcomes of an effective HRPP? Can they be empirically evaluated—and, if so, can that data help drive best practices? Those are just some of the questions being tackled by the Consortium to Advance Effective Research…

Read More

Advance notice of mysterious rule puts drug-pricing people on edge

Politico Prescription Pulse, October 22, 2018
Sarah Karlin-Smith, featuring Holly Fernandez Lynch (Former Executive Director)

From the article:  Holly Fernandez Lynch, a medical ethicist at the University of Pennsylvania, wonders whether FDA will audit third-party invoices to make sure manufacturers aren’t profiting from these sales. She sees pros and cons in…

Read More

Trump Administration Wants TV Drug Ads To Include A Price

WFPL, October 20, 2018
Lisa Gillespie, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: Rachel Sachs, an associate professor of law and a drug regulation expert at Washington University, said that the proposal is very narrow and doesn’t do anything for transparency for many drugs.

Read More

Rachel Sachs of Washington University on the USMCA

SiriusXM Radio, October 18, 2018
Joe Madison the Black Eagle, interviewing Rachel Sachs

From the article: NAFTA (the North American Free Trade Agreement) has become the USCMA (U.S., Mexico, and Canada Agreement). What does that mean for you? Professor Rachel Sachs of Washington University in St. Louis explains why some problems, like…

Read More

5 questions on the Trump admin’s bid to mandate prices in drug ads

Biopharma Dive, October 16, 2018
Ned Pagliarulo and Andrew Dunn, quoting Rachel Sachs

From the article: HHS argues that it has the authority to require price disclosures in ads through the Social Security Act, which tasks it with the "efficient" administration of the Medicare and Medicaid programs. The agency says the rule would help…

Read More

Trump issues rule to require drug prices in TV ads, rejecting industry plan

Politico, October 15, 2018
Sarah Karlin Smith, quoting Rachel Sachs

From the article: A majority of voters tends to support the transparency move but remains skeptical of whether it will lead to lower drug costs. A July POLITICO/Harvard poll found 63 percent of Americans favored requiring drug advertisements to include…

Read More

Should TV Drug Ads Be Forced To Include A Price? Trump’s Team Says Yes

NPR's Morning Addition, October 15, 2018
Shefali Luthra and Sarah Lane Tribble, quoting Rachel Sachs

From the article: "It is noteworthy that the government is unwilling to take enforcement action," said Rachel Sachs, an associate professor of law at Washington University in St. Louis and an expert in drug-pricing regulation. The rule might…

Read More

Drugmakers may have to disclose prices of medicine in television ads

Washington Post, October 15, 2018
Amy Goldstein and Carolyn Y Johnson, quoting Rachel Sachs

From the article: Rachel Sachs, an associate professor of law at Washington University in St. Louis School of Law, said that it is unclear how or why disclosures would reduce drug prices. “The administration has not yet advanced a theory for…

Read More

Drugmakers may have to disclose prices of medicine in television ads

Washington Post, October 15, 2018
Amy Goldstein and Carolyn Y Johnson, quoting Rachel Sachs

From the article: Rachel Sachs, an associate professor of law at Washington University in St. Louis School of Law, said that it is unclear how or why disclosures would reduce drug prices. “The administration has not yet advanced a theory for…

Read More

Senators question basis for FDA’s digital health pre-cert pilot

Medical Design and Outsourcing, October 12, 2018
Chris Newmarker, featuring work by I. Glenn Cohen (Faculty Director)

From the article:  In another post on Aug. 16, 2017, on Health Affairs, Nathan G. Cortez, Nicolas Terry, and I. Glenn Cohen described the pre-cert program as “an experiment in medical product regulation” that…

Read More

The exciting new idea hospitals have to bring down drug prices

Vox, October 8, 2018
Dylan Scott, quoting Rachel Sachs (Academic Fellow Alumna)

From the article:  To fully appreciate the scope of the generic drug pricing problem, remember that the Justice Department and 45 states are currently in court accusing generic drug makers of price fixing and costing Americans more…

Read More

In The Battle To Control Drug Costs, Old Patent Laws Get New Life

Kaiser Health News, October 5, 2018
Shefali Luthra, quoting Rachel Sachs and W. Nicholson Price (Academic Fellow Alumni)

From the article:  Simply taking a patent doesn’t bring down prices, either. There are other ways manufacturers gain favorable market positioning for specific drugs, said Rachel Sachs, an associate law professor at Washington University…

Read More

Outbreak Week: How prepared are we for the next health crisis?: Petrie-Flom hosts several events during Harvard series on pandemic preparedness

Harvard Law Today, October 5, 2018

From the article:  Outbreak Week, led by the Harvard Global Health Institute, was a unique multidisciplinary effort investigating and engaging with epidemic and pandemic…

Read More

From cyborgs to sex robots: University of Minnesota professor studies how brain science is changing

Star Tribune, October 3, 2018
Richard Chin, featuring Francis X. Shen (Senior Fellow)

From the article: Francis Shen spends a lot of time thinking about transhuman cyborgs, brain-wave lie detectors, sex robots and terrorists hacking into devices implanted in our heads. And, no, he’s not a science…

Read More

When Your Dreams of Motherhood Are Destroyed

Marie Claire, October 1, 2018
Kayla Webley Adler, quoting I. Glenn Cohen (Faculty Director)

From the article:  Neither major political party is expected to push for more regulation. Democrats aren’t likely to touch fertility because of how close the issue is to the abortion debate. “Any attempt to regulate reproductive technology almost…

Read More

The Health 202: Trump vowed drug companies would lower prices. That hasn’t happened yet.

The Washington Post, October 1, 2018
Paulina Firozi, quoting Rachel Sachs (Academic Fellow Alumna)

From the article:  The AP found in the two months after Trump’s prediction of major cuts,  price increases outpaced decreases by a 16.5-to-1 ratio. During that time there were 395 price increases and 24 decreases.…

Read More

Yes, PTAB proceedings against Orange Book patents are on the up. No, they’re not wiping them out

IAM Media, October 1, 2018
Adam Houldsworth, featuring work by Jonathan Darrow

From the article: Further data has emerged showing that the Patent Trial and Appeal Board (PTAB) is far from the “death squad” that many in the US life sciences industries fear that it may be becoming. A…

Read More